Randomized controlled trials in pregnancy: Scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison

Addiction

Volumn 106, Issue 7, 2011, Pages 1355-1362

  Unger, Annemarie ^a   Jagsch, Reinhold ^b   Jones, Hendree ^c   Arria, Amelia ^d   Leitich, Harald ^a   Rohrmeister, Klaudia ^a   Aschauer, Constantin ^a   Winklbaur, Berndadette ^a   Bäwert, Andjela ^a   Fischer, Gabriele ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Buprenorphine; Methadone; Neonatal abstinence syndrome; Opioid dependence; Opioid maintenance treatment; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BIRTH WEIGHT; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MULTICENTER STUDY; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BIRTH WEIGHT; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT, NEWBORN; MALE; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957971086     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03440.x     Document Type: Article

References (35)

1. Goodrum L., Hankins G., Jermain D., Chanaud C. Conference report: complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials. J Womens Health 2003; 12: 835-7.
2. Chervenak F. A., McCullough L. B. Ethics research and the pregnant patient. Curr Womens Health Rep 2003; 3: 505-9.
3. Selby P., Kapur B., Hackman R., Koren G. 'No one asked the baby'-an ethical issue in placebo-controlled trials in pregnant smokers. Can J Clin Pharmacol 2005; 12: e180-81.
4. McCullough L. B., Coverdale J. H., Chervenak F. A. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am J Obstet Gynecol 2005; 193: 901-7.
5. US Congress. National Institute of Health revitalization amendment. Public Law 103-43. 6-10-1993; 1993.
6. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008; 103: 1429-40.
7. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
8. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. etal. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-81.
9. Fischer G., Johnson R. E., Eder H., Jagsch R., Peternell A., Weninger M. etal. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000; 95: 239-44.
10. Johnson R. E., Jones H. E., Jasinski D. R., Svikis D. S., Haug N. A., Jansson L. M. etal. Buprenorphine treatment of opioid dependent women maternal and neonatal outcomes. Drug Alcohol Depend 2001; 63: 97-103.
11. Choo R., Huestis M., Schroeder J., Shin A., Jones H. E. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75: 253-60.
12. Jones H. E., Kaltenbach K., Heil S., Stine S., Coyle M., Arria A. etal. Neonatal abstinence syndrome following methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-41.
13. Jones H. E., Martin P. R., Heil S. H., Kaltenbach K., Selby P., Coyle M. G. etal. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35: 245-59.
14. Unger A., Martin P., Kaltenbach K., Stine S., Heil S., Jones H. etal. Clinical Characteristics of central European and North American samples of pregnant women screened for opioid agonist treatment. Eur Addict Res 2010; 16: 99-107. (doi: 10.1159/000284683).
15. Stine S. M., Heil S. H., Kaltenbach K., Martin P. R., Coyle M. G., Fischer G. etal. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse 2009; 35: 429-33.
16. First M. B., Spitzer R. L., Gibbon M., Williams J. B. W. Structured clinical interview for DSM-IV Axis I disorders. New York: Biometrics Research, New York State Psychiatric Institute, 1996.
17. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. etal. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
18. Jones H. E., Harrow C., O'Grady K. E., Crocetti M., Jansson L. M., Kaltenbach K. Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J Opioid Manag 2010; 6: 409-13.
19. Finnegan L., Kaltenbach K. Studies of prenatal drug exposure and environmental research issues: the benefits of integrating research within a treatment program. NIDA Res Monogr 1992; 117: 259-70.
20. Jones H. E., Haug N., Silverman K., Stitzer M., Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 2001; 61: 297-306.
21. Terplan M., Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev 2007; 4: CD006037. doi: 10.1002/14651858.CD006037.pub2.
22. Lussier J. P., Heil S. H., Mongeon J. A., Badger G. J., Higgins S. T. A meta-analysis of voucher based re-enforcement therapy for substance use disorders. Addiction 2006; 101: 192-203.
23. Winklbaur B., Baewert A., Jagsch R., Rohrmeister K., Metz V., Aeschbach Jachmann C. etal. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers implications for treatment. Eur Addict Res 2009; 15: 150-6.
24. Jones H. E., Heil S. H., O'Grady K. E., Martin P. R., Kaltenbach K., Coyle M. G. etal. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant samples. Am J Drug Alcohol Abuse 2009; 35: 375-80.
25. LeJeune C., Simmat-Durand L., Gourarier L., Aubisson S, Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend 2006; 82: 250-7.
26. Ebner N., Rohrmeister K., Winklbaur B., Baewert A., Jagsch R., Peternell A. etal. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007; 87: 131-8.
27. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96: 69-78.
28. Bakstad B., Sarfi M., Welle-Strand G. K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009; 15: 128-34.
29. Marquet P., Lavignasse P., Gautier P. M. Case study of neonates born to mothers undergoing buprenorphine maintenance treatment. In: Kintz P., Marquet P., editors. Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press; 2002, p. 23-35.
30. Lim S., Prasad M., Samuels P., Gardner D., Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009; 200: 70.e1-5.
31. Kahila H., Saisto T., Kivitie-Kallio S., Haukkamaa M., Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007; 86: 185-90.
32. Schindler S., Eder H., Ortner R., Rohrmeister K., Langer M., Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003; 98: 103-10.
33. Cleary B., Donnelly J., Strawbridge J., Gallagher P. J., Fahey T., Clarke M. etal. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010; 105 2071-4.
34. Fischer G. Treatment of opioid dependence in pregnant women. Addiction 2000; 95: 1141-4.
35. Fischer G. Our ethical responsibility. Addiction 2000; 95: 1769-70.